JP2004527449A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004527449A5 JP2004527449A5 JP2001559487A JP2001559487A JP2004527449A5 JP 2004527449 A5 JP2004527449 A5 JP 2004527449A5 JP 2001559487 A JP2001559487 A JP 2001559487A JP 2001559487 A JP2001559487 A JP 2001559487A JP 2004527449 A5 JP2004527449 A5 JP 2004527449A5
- Authority
- JP
- Japan
- Prior art keywords
- references
- sequence list
- list
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18268500P | 2000-02-15 | 2000-02-15 | |
| US09/788,110 US7388071B2 (en) | 2000-02-15 | 2001-02-15 | Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response |
| PCT/US2001/005143 WO2001060391A1 (en) | 2000-02-15 | 2001-02-15 | A universal vaccine and method for treating cancer employing telomerase reverse transcriptase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004527449A JP2004527449A (ja) | 2004-09-09 |
| JP2004527449A5 true JP2004527449A5 (enExample) | 2005-01-20 |
Family
ID=22669572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001559487A Withdrawn JP2004527449A (ja) | 2000-02-15 | 2001-02-15 | テロメラーゼ逆転写酵素を用いる癌を治療するための万能ワクチンと方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US7388071B2 (enExample) |
| JP (1) | JP2004527449A (enExample) |
| AU (1) | AU2001241533A1 (enExample) |
| CA (1) | CA2399816A1 (enExample) |
| WO (1) | WO2001060391A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL129103A0 (en) | 1996-10-01 | 2000-02-17 | Geron Corp | Human telomerase catalytic subunit and pharmaceutical compositions containing same |
| US6475789B1 (en) | 1996-10-01 | 2002-11-05 | University Technology Corporation | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
| US7585622B1 (en) | 1996-10-01 | 2009-09-08 | Geron Corporation | Increasing the proliferative capacity of cells using telomerase reverse transcriptase |
| US7622549B2 (en) | 1997-04-18 | 2009-11-24 | Geron Corporation | Human telomerase reverse transcriptase polypeptides |
| US7413864B2 (en) | 1997-04-18 | 2008-08-19 | Geron Corporation | Treating cancer using a telomerase vaccine |
| US7402307B2 (en) | 1998-03-31 | 2008-07-22 | Geron Corporation | Method for identifying and killing cancer cells |
| FR2812087B1 (fr) * | 2000-07-21 | 2007-05-11 | Inst Nat Sante Rech Med | Procede de criblage de peptides utilisables en immunotherapie |
| GB0105238D0 (en) * | 2001-03-02 | 2001-04-18 | Norsk Hydro As | Vaccines |
| ES2323895T3 (es) * | 2005-05-09 | 2009-07-27 | Vaxon Biotech | Uso de peptidos nativos y sus derivados optimizados para vacunacion. |
| US20090202499A1 (en) * | 2006-01-19 | 2009-08-13 | The Regents Of The University Of California | Human Telomerase Reverse Transcriptase Peptides |
| EP2453243A1 (en) * | 2010-11-11 | 2012-05-16 | Cosmo S.p.A. | Method for the diagnosis and/or follow up of the evolution of a tumor |
| AU2017208848A1 (en) | 2016-01-19 | 2018-07-12 | Pfizer Inc. | Cancer vaccines |
| CN109069575A (zh) * | 2016-02-23 | 2018-12-21 | 毛里齐奥·扎内蒂 | 通用癌症疫苗 |
| MX2019003722A (es) | 2016-09-30 | 2019-09-26 | Univ Pennsylvania | Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan. |
| FR3097123A1 (fr) * | 2019-06-11 | 2020-12-18 | Vaxon Biotech | Combinaison de marqueurs pour prédire la réponse à Vx-001 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4622952A (en) * | 1983-01-13 | 1986-11-18 | Gordon Robert T | Cancer treatment method |
| US5030621A (en) * | 1987-04-23 | 1991-07-09 | Bystryn Jean Claude | Shed melanoma antigen compositions |
| CA2047244C (en) * | 1989-02-24 | 2002-09-17 | Zanetti Maurizio | Genetically engineered immunoglobulins |
| IE910820A1 (en) * | 1990-03-22 | 1991-09-25 | Sloan Kettering Inst Cancer | Gp75 as a tumor vaccine for melanoma |
| SG52492A1 (en) | 1992-08-07 | 1998-09-28 | Cytel Corp | Hla binding peptides and their uses |
| WO1994024267A1 (en) * | 1993-04-20 | 1994-10-27 | Robinson, William, S. | Methods and materials for treatment of individuals infected with intracellular infectious agents |
| US6106829A (en) * | 1995-01-20 | 2000-08-22 | Human Genome Sciences, Inc. | Human prostatic specific reductase |
| US5658234A (en) * | 1995-07-24 | 1997-08-19 | J. D. Technologies, Inc. | Method for treating tumors |
| US6093809A (en) * | 1996-10-01 | 2000-07-25 | University Technology Corporation | Telomerase |
| CA2347067C (en) * | 1998-03-31 | 2013-09-17 | Geron Corporation | Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer |
| EP1085892A4 (en) | 1998-06-12 | 2002-07-17 | Sloan Kettering Inst Cancer | VACCINATION STRATEGY FOR PREVENTING AND TREATING CANCERS |
| US7030211B1 (en) | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
| DE69934426T2 (de) * | 1998-10-29 | 2007-10-04 | Whitehead Institute For Biomedical Research, Cambridge | KREBSIMMUNTHERAPIE UND KREBSDIAGNOSE UNTER VERWENDUNG UNIVERSELLER TUMORASSOZIIERTER ANTIGENE EINSCHLIESSLICH hTERT |
| AU781376B2 (en) | 1999-04-09 | 2005-05-19 | Biomira Inc. | Telomerase-specific cancer vaccine |
| FR2812087B1 (fr) * | 2000-07-21 | 2007-05-11 | Inst Nat Sante Rech Med | Procede de criblage de peptides utilisables en immunotherapie |
| US7078491B1 (en) * | 2000-09-21 | 2006-07-18 | Amgen Inc. | Selective binding agents of telomerase |
| EP2295575A3 (en) * | 2000-12-04 | 2011-07-06 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| GB0031430D0 (en) * | 2000-12-22 | 2001-02-07 | Norsk Hydro As | Polypeptides |
| US6992176B2 (en) * | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
-
2001
- 2001-02-15 JP JP2001559487A patent/JP2004527449A/ja not_active Withdrawn
- 2001-02-15 CA CA002399816A patent/CA2399816A1/en not_active Abandoned
- 2001-02-15 AU AU2001241533A patent/AU2001241533A1/en not_active Abandoned
- 2001-02-15 WO PCT/US2001/005143 patent/WO2001060391A1/en not_active Ceased
- 2001-02-15 US US09/788,110 patent/US7388071B2/en not_active Expired - Fee Related
-
2008
- 2008-04-25 US US12/150,164 patent/US8697836B2/en not_active Expired - Fee Related